NextCure, Inc.
Current- Director 2020 to present
Skip to record
Executive record
Alpha ID: alpha:person:john-g-houston-ph-dVersion: public-0As of: 2026-10-01
Not yet claimed9 published Claims4 sources
- Director
Leadership, in context.
Connect capital, control, accountability, and evidence.
Explore the record
ResponsibilitiesInspect board appointments and committee mandates.ExperienceReview career history and qualifications in context.Economic interestsExamine disclosed incentives and ownership.Key Claims
Biography
Dr. Houston is the former President and CEO of Arvinas Inc. and previously held senior R&D leadership roles at Bristol Myers Squibb, where he oversaw discovery biology and technology departments.
Alpha editorial summary written from the cited sources below. It does not change any Claim on this record.
Board service
Boards
Claims
Experience
Experience coverage
No published Claims are available in this section of the public record. This does not establish that the information is undisclosed or that no relevant facts exist.
Review evidence coverageCompensation
Compensation coverage
No published Claims are available in this section of the public record. This does not establish that the information is undisclosed or that no relevant facts exist.
Review evidence coverageConflicts and accountability
Only disclosed facts and public registers appear here. Executive records carry no credit, personal litigation, background screening or underwriting views. None observed is not a clearance.
Evidence, history and coverage
Additional published Claims
Published evidence records
4 evidence records, matching Agent View. Records may refer to different locations or observations in the same document. This count is not a count of independent corroborating sources.
NXTC DEF 14A director slate
sec filing · Source published: Apr 24, 2026 · Retrieved: Apr 28, 2026
Supports 5 claims
- AI and ML experience: AI and ML experience: not identified in the cited filing · Claim reviewed: Apr 28, 2026
- Board role: Board role: Director · Claim reviewed: Apr 28, 2026
- Committee assignments: Committee assignments: Compensation · Claim reviewed: Apr 28, 2026
- Cybersecurity experience: Cybersecurity experience: not identified in the cited filing · Claim reviewed: Apr 28, 2026
- Technology background: Technology background reported in filings · Claim reviewed: Apr 28, 2026
NextCure, Inc. director board source
sec filing · Source published: Apr 24, 2026 · Retrieved: May 3, 2026
Supports 3 claims
- Board independence: Independent director · Claim reviewed: May 3, 2026
- Board membership: Serves on the board of NextCure, Inc. · Claim reviewed: May 3, 2026
- Committee assignments: No committee assignment disclosed in the cited filing · Claim reviewed: May 3, 2026
Open source
sec proxy · Source published: Apr 24, 2026 · Retrieved: Apr 24, 2026
Supports 1 claim
- Professional Role: Director at NextCure, Inc. · Claim reviewed: Apr 28, 2026
Open source
public source · Source published: Date unavailable · Retrieved: Date unavailable
Supports 1 claim
- Board membership: Serves on the board of NextCure, Inc. · Claim reviewed: May 3, 2026
No published record changes are available in this projection.
Identity
unclaimed
Evidence
corroborated
Evaluation
Unknown
Monitoring
Unknown
Authority
Unknown
Freshness
Observed 2026-10-01
- Biography
- published
- Board service
- published
- Executive career
- not observed
- Education and qualifications
- not observed
- Compensation
- not observed
- Conflicts and accountability
- published
- Background screening
- out of scope